Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

707 results about "Lymph node" patented technology

A lymph node or lymph gland is an ovoid or kidney-shaped organ of the lymphatic system and the adaptive immune system. Lymph nodes are widely present throughout the body and are linked by the lymphatic vessels as a part of the circulatory system. They are major sites of B and T lymphocytes and other white blood cells. Lymph nodes are important for the proper functioning of the immune system, acting as filters for foreign particles and cancer cells, but they do not have a detoxification function.

Nanoparticles for immunotherapy

Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)

Nanoparticles for immunotherapy

Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics. Surface chemistries and chemical formulations for the nanoparticles are described.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)

Compositions and methods for the treatment of cancer

InactiveUS20020128228A1Reducing and avoiding adverse effectImprove toleranceBiocideAnimal repellantsIntestinal structureCancer prevention
This invention relates to compositions comprising temozolomide and thalidomide which can be used in the treatment or prevention of cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof. A particular composition comprises temozolomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof. The invention also relates to methods of treating or preventing cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof, which comprise the administration of temozolomide and thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of cancer chemotherapy or radiation therapy which comprise the administration of temozolomide and thalidomide to a patient in need of such reduction or avoidance.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

System and method for capturing body tissue samples

A system and method provides for the capture of body tissue samples such as lymph nodes. The system includes a bag formed of a flexible material having a first end opened for receiving the body tissue sample and a second end which is closed to the body tissue sample but which permits a vacuum to be pulled through the bag. The system further includes a vacuum tube in which the body tissue sample capture bag may be disposed and a vacuum source that pulls a vacuum through the body tissue sample capture bag for pulling the body tissue sample into the bag through the opened end of the bag.
Owner:GYRUS ACMI INC (D B A OLYMPUS SURGICAL TECH AMERICA)

Systems and methods for treating, diagnosing and predicting the occurence of a medical condition

Methods and systems are provided that use clinical information, molecular information and computer-generated morphometric information in a predictive model for predicting the occurrence (e.g., recurrence) of a medical condition, for example, cancer. In an embodiment, a model that predicts prostate cancer recurrence is provided, where the model is based on features including seminal vesicle involvement, surgical margin involvement, lymph node status, androgen receptor (AR) staining index of tumor, a morphometric measurement of epithelial nuclei, and at least one morphometric measurement of stroma. In another embodiment, a model that predicts clinical failure post prostatectomy is provided, wherein the model is based on features including biopsy Gleason score, lymph node involvement, prostatectomy Gleason score, a morphometric measurement of epithelial cytoplasm, a morphometric measurement of epithelial nuclei, a morphometric measurement of stroma, and intensity of androgen receptor (AR) in racemase (AMACR)-positive epithelial cells.
Owner:AUREON LAB INC +2

Automated method and system for computerized image analysis for prognosis

ActiveUS7418123B2Improved decision making regarding treatment optionsImage enhancementImage analysisTreatment optionsLesion feature
An automated method for determining prognosis based on an analysis of abnormality (lesion) features and parenchymal features obtained from medical image data of a patient. The techniques include segmentation of lesions from radiographic images, extraction of lesion features, and a merging of the features (with and without clinical information) to yield as estimate of the prognosis for the specific case. An example is given for the prognosis of breast cancer lesions using mammographic data. A computerized image analysis system for assessing prognosis combines the computerized analysis of medical images of cancerous lesions with the training-based methods of assessing prognosis of a patient, using indicators such as lymph node involvement, presence of metastatic disease, local recurrence, and / or death. It is expected that use of such a system to assess the severity of the disease will aid in improved decision-making regarding treatment options.
Owner:UNIVERSITY OF CHICAGO

Systems and methods for treating diagnosing and predicting the occurrence of a medical condition

Methods and systems are provided that use clinical information, molecular information and computer-generated morphometric information in a predictive model for predicting the occurrence (e.g., recurrence) of a medical condition, for example, cancer. In an embodiment, a model that predicts prostate cancer recurrence is provided, where the model is based on features including one or more (e.g., all) of biopsy Gleason score, seminal vesicle invasion, extracapsular extension, preoperative PSA, dominant prostatectomy Gleason grade, the relative area of AR+ epithelial nuclei, a morphometric measurement of epithelial nuclei, and a morphometric measurement of epithelial cytoplasm. In another embodiment, a model that predicts clinical failure post-prostatectomy is provided, wherein the model is based on features including one or more (e.g., all) of dominant prostatectomy Gleason grade, lymph node invasion status, one or more morphometric measurements of lumen, a morphometric measurement of cytoplasm, and average intensity of AR in AR+ / AMACR− epithelial nuclei.
Owner:AUREON LAB INC +1

Photoacoustic detection of analytes in solid tissue and detection system

A preferred system for detecting an analyte in solid tissue, such as an intact lymph node, in vitro includes a laser arranged to generate a pulsed laser beam into solid tissue, which can be a fully intact lymph node. An acoustic sensor, and preferably at least three acoustic sensors are arranged in different positions to span a three dimensional space, such as in an X, Y and Z coordinate system, to detect photoacoustic signals generated within the lymph node. At least one computer receives signals from the acoustic sensor(s). The computer determines the presence or absence of, and preferably the position of analyte, from the signals and the timing of the signals. A preferred method for detecting an analyte in a lymph node in vitro includes exposing an extracted lymph node to a pulsed laser beam. A photoacoustic signal is sensed. The photoacoustic signal is analyzed to confirm the presence or absence of an analyte in the lymph node. Preferably, multiple photoacoustic signals are sensed from sensors that span a three dimensional space and the position of analyte is also determined.
Owner:UNIVERSITY OF MISSOURI

Molecular indicators of breast cancer prognosis and prediction of treatment response

The present invention relates to quantitative molecular indicators that can guide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the invention concerns certain genes, the varied expression of which indicates the likelihood of recurrence of surgically resected breast cancer in patients who are not treated with a therapeutic agent in the adjuvant setting. In addition, the invention concerns the use of quantitative measurement of the expression of certain genes, including the ESR1 gene, that measure as a continuous variable, to determine (a) the likelihood of a beneficial response to the anti-estrogen therapeutic agent, such as tamoxifen; and (b) the potential magnitude of beneficial response to chemotherapy.
Owner:MICROSOFT CORP +2

Automated Determination of Lymph Nodes in Scanned Images

Techniques include automatically detecting a lymph node in a scanned image of a body without human intervention, using one or more of three approaches. First, a subset of scanned images is determined, which belongs to one anatomical domain. A search region for lymph tissue is in a particular spatial relationship outside an anatomical object in the domain. Second, scanned images are segmented without human intervention to determine a boundary of a particular lymph node. The scanned images and outline data are received. Some of these embodiments automatically segment by determining an external marker, based on the outline data, and an internal marker, based on a geometric center of the outline data or thresholds determined automatically inside detected edges, or both, for a marker-controlled watershed algorithm. Third, based on lymph node data at a particular time, a second scanned image at a different time is segmented automatically, without human intervention.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Methods and compositions for delivery and retention of active agents to lymph nodes

InactiveUS7060689B2FlexibilityIncreasing active agent localizationGenetic material ingredientsNanomedicineMedicineActive agent
The present invention is directed to delivery and retention of active agents to targeted lymph nodes in a mammal using a ligand / anti-ligand pair. More particularly, the invention involves methods, compositions, and kits for delivery and retention of active agents to targeted lymph nodes using compositions comprising a ligand-colloid moiety and compositions comprising an anti-ligand. Active agents may be associated with one or more of the colloid, ligand, or anti-ligand. Conjugation of the ligand and anti-ligand after administration permits retention of aggregated colloid complex in targeted lymph nodes.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

System and method for achieving regular slow ventricular rhythm in response to atrial fibrillation

InactiveUS20070083242A1Decrease ventricular rateEasy to adjustElectrotherapyVentricular rateAtrial cavity
A system (10) for achieving a desired cardiac rate and cardiac rhythm in response to atrial fibrillation in a heart includes an atrial fibrillation (AF) detector (40) for detecting AF. The system also includes an atrioventricular node vagal stimulator (AVN-VS) (30) for stimulating vagal nerves associated with an atrioventricular (AV) node of the heart. The system further includes an on-demand pace maker (40) for providing ventricular pacing stimulation to the heart. A control unit (20) is operatively connected with the AF detection device, the AVN-VS device, and the on-demand pacing device. The control unit is responsive to AF detection by the AF detector to cause the AVN-VS to stimulate the vagal nerves to help reduce the ventricular rate of the heart. The control unit is further responsive to AF detection by the AF detector to cause the on-demand pace maker to help regulate the ventricular rate of the heart.
Owner:THE CLEVELAND CLINIC FOUND

Target tissue localization device

A target tissue localization device includes a tubular mesh anchor element that is secured to a placement device. In use, the localization device is passed through the patient's skin to the target tissue, creating a tissue track. The tubular mesh anchor element is located at the target tissue and expanded from a contracted to an expanded configuration. Methods for localizing a lymph node are also described. After determining the position of the lymph node, a localization device, which includes an anchor element, is localized near or within the lymph node. The anchor element is then expanded.
Owner:ARTEMIS MEDICAL

Apoptosis inducing molecule II and methods of use

The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.
Owner:HUMAN GENOME SCI INC

System and Method For Labeling and Identifying Lymph Nodes In Medical Images

A method for assigning a lymph node in a medical image with an anatomical name, the method including: identifying landmarks in a medical image; computing features relative to the landmarks given a location of a lymph node in the medical image; and assigning an anatomical name to the location of the lymph node by using a classifier that compares the computed features with classification rules.
Owner:SIEMENS HEALTHCARE GMBH +1

Techniques for Segmentation of Lymph Nodes, Lung Lesions and Other Solid or Part-Solid Objects

Techniques for segmentation include determining an edge of voxels in a range associated with a target object. A center voxel is determined. Target size is determined based on the center voxel. In some embodiments, edges near the center are suppressed, markers are determined based on the center, and an initial boundary is determined using a watershed transform. Some embodiments include determining multiple rays originating at the center in 3D, and determining adjacent rays for each. In some embodiments, a 2D field of amplitudes is determined on a first dimension for distance along a ray and a second dimension for successive rays in order. An initial boundary is determined based on a path of minimum cost to connect each ray. In some embodiments, active contouring is performed using a novel term to refine the initial boundary. In some embodiments, boundaries of part-solid target objects are refined using Markov models.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition

Methods and systems are provided that use clinical information, molecular information and computer-generated morphometric information in a predictive model for predicting the occurrence (e.g., recurrence) of a medical condition, for example, cancer. In an embodiment, a model that predicts prostate cancer recurrence is provided, where the model is based on features including one or more (e.g., all)of biopsy Gleason score, seminal vesicle invasion, extracapsular extension, preoperative PSA, dominant prostatectomy Gleason grade, the relative area of AR+ epithelial nuclei, a morphometric measurement of epithelial nuclei, and a morphometric measurement of epithelial cytoplasm. In another embodiment, a model that predicts clinical failure post-prostatectomy is provided, wherein the model is based on features including one or more (e.g., all) of dominant prostatectomy Gleason grade, lymph node invasion status, one or more morphometric measurements of lumen, a morphometric measurement of cytoplasm, and average intensity of AR in AR+ / AMACR- epithelial nuclei.
Owner:AUREON LAB INC

Nanoparticles for immunotherapy

Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics. Surface chemistries and chemical formulations for the nanoparticles are described.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)

Immunostimulatory compositions and methods of use thereof

Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject.
Owner:MASSACHUSETTS INST OF TECH

Adjuvant for transcutaneous immunization

A transcutaneous immunization system delivers antigen to immune cells without perforation of the skin, and induces an immune response in an animal or human. The system uses an adjuvant, preferably an ADP-ribosylating exotoxin, to induce an antigen-specific immune response (e.g., humoral and / or cellular effectors) after transcutaneous application of a formulation containing antigen and adjuvant to intact skin of the animal or human. The efficiency of immunization may be enhanced by adding hydrating agents (e.g., liposomes), penetration enhancers, or occlusive dressings to the transcutaneous delivery system. This system may allow activation of Langerhans cells in the skin, migration of the Langerhans cells to lymph nodes, and antigen presentation.
Owner:UNITED STATES OF AMERICA

Method of Diagnosing Breast Cancer

InactiveUS20070269432A1Preventing metastasis of breast cancerMetastasis of breast cancer can be treated or preventedOrganic active ingredientsCompound screeningBreast cancer metastasisNormal cell
Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates between BRC cells and normal cells. In another embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates among BRC cells, between DCIS and IDC cells. The present invention further provides means for predicting and preventing breast cancer metastasis using BRC-associated genes having unique altered expression patterns in breast cancer cells with lymph-node metastasis. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of breast cancer, methods of treating breast cancer and method for vaccinating a subject against breast cancer.
Owner:ONCOTHERAPY SCI INC

Antibodies that specifically bind to TL5

InactiveUS20050129614A1Animal cellsHybrid immunoglobulinsAutoimmune diseaseReactive lymphadenopathy
The present invention relates to antibodies and related molecules that specifically bind to TL5. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including autoimmune disease, rheumatoid arthritis, graft rejection, graft vs. host disease, and lymphadenopathy. The invention also relates to nucleic acid molecules encoding anti-TL5 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer as well as immune system diseases and disorders including autoimmune disease, rheumatoid arthritis, graft rejection, graft vs. host disease, and lymphadenopathy, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to TL5.
Owner:HUMAN GENOME SCI INC

Immunotherapy for immune suppressed patients

InactiveUS20060194242A1Organic active ingredientsPeptide/protein ingredientsDendritic cellCellular immunodeficiency
The present invention provides compositions of a natural cytokine mixture (NCM) for treating a cellular immunodeficiency characterized by T lymphocytopenia, one or more dendritic cell functional defects such as those associated with lymph node sinus histiocytosis, and / or one or more monocyte functional defects such as those associated with a negative skin test to NCM. The invention includes methods of treating these cellular immunodeficiences using the NCM of the invention. The compositions and methods are useful in the treatment of diseases associated with cellular immunodeficiencies such as cancer. Also provided are compositions and methods for reversing tumor-induced immune suppression comprising a chemical inhibitor and a non-steroidal anti-inflammatory drug (NSAID). The invention also provides a diagnostic skin test comprising NCM for predicting treatment outcome in cancer patients.
Owner:IRX THERAPEUTICS

Cardiac pacing using the inferior nodal extension

A device and method for providing stimulation to an inferior nodal extension of a heart. The method includes providing a lead comprising an electrode, positioning the electrode proximate an inferior nodal extension of a heart, and effecting at least one of activation, deactivation, or modulation of the electrode to provide stimulation to the inferior nodal extension.
Owner:WASHINGTON UNIV IN SAINT LOUIS

Tissue specific promoters and transgenic mouse for the screening of pharmaceuticals

InactiveUS6313373B1Restores promoter activityVectorsSugar derivativesHuman papillomavirusPromoter activity
The present invention provides human involucrin (hINV) sequences having tissue specific and cell type specific promoter activity. The sequences provided herein direct expression to suprabasal cells of stratifying epithelia. The invention further provides methods for the production of transgenic animals which contain a hINV promoter sequence which directs the expression of human papillomavirus 16 oncogenes (or other oncogenes). These animals display cervical and epidermal hyperplasias as well as cancer of the trachea, esophagus, colon, epidermis, anus / rectum, lymph nodes, spleen and lung. The animals of the invention provide a useful model for screening potential anti-neoplastic compounds, carcinogens, and co-carcinogens for a number of cancers.
Owner:CASE WESTERN RESERVE UNIV

Molecules that home to various selected organs or tissues

The present invention provides molecules that selectively home to various normal organs or tissues, including to lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut; and provides molecules that selectively home to tumor bearing organs or tissues, including to pancreas bearing a pancreatic tumor or to lung bearing a lung tumor. The invention also provides conjugates, comprising an organ or tissue homing molecule linked to a moiety. Such a moiety can be, for example, a therapeutic agent or a detectable agent. In addition, the invention provides methods of using an organ homing molecule of the invention to identify a particular organ or tissue by contacting the organ or tissue with a molecule of the invention. The invention also provides methods to diagnose or treat a pathology of the lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut by administering to a subject having or suspected of having a pathology a molecule that homes to the selected organ or tissue. The invention further provides methods of identifying a target molecule in lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut.
Owner:THE BURNHAM INST

Method and system for spatial segmentation of anatomical structures

Spatial segmentation of lymph nodes in a 3-D medical image is automatically determined, based on a set of inputs provided by a user which define a low number of initial conditions for segmentation. In some embodiments, the automation comprises producing a lymph node segmentation from the 3-D image based on a 2-D image slice and a representative line segment on that slice. In some embodiments, segmentation comprises a two tiered approach (2-D segmentation, followed by 3-D segmentation) based on adaptation of the level set framework to the particular conditions of lymph node segmentation.
Owner:PHILIPS MEDICAL SYST TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products